Fig. 1

Schematic representation of the experimental design and group composition. The study comprises of 3 groups; evaluating the effects of FSH and XAR™ formulation on mouse ovaries in Group A and the curative preventive effects of XAR™ treatment after chemotherapy in females – Group B and males – Group C. Group A comprises of 5 sub-groups; control, mice treated with only FSH for 2 and 4 days, and with only XAR™ formulation for 2 and 4 days respectively. The mice were sacrificed on Day 7. Group B for female mice chemoablation studies comprises of 6 sub-groups; control, mice treated with only XAR™ formulation, curative control – Busulfan (Bu) – Cyclophosphamide (Cy) treatment, curative treatment – post 30 days of Bu-Cy treatment, the XAR™ treatment was continued for 2 weeks, preventive control—Bu-Cy treatment and preventive treatment—Bu-Cy- XAR™ treatment, wherein XAR treatment was initiated 2 days prior to Bu-Cy and continued until Day 30. Group C for male mice chemoablation studies comprises of 6 sub-groups; control, mice treated with only XAR™ formulation, curative control – only Bu treatment, curative treatment – post 30 days of Bu treatment, the XAR™ treatment was continued for 2 weeks, preventive control—Bu treatment and preventive treatment—Bu-Cy- XAR™ treatment, wherein XAR treatment was initiated 2 days prior to Bu and continued until Day 30. In Group B and C, the mice were sacrificed as per the defined end-point on Day 30 or Day 45